VivoSight OCT Publications surpass 800

With 73 new papers published in the past 12 months alone across Dermatology, Microneedle Array Patches, and Oral Medicine. This growing body of evidence highlights the expanding adoption of VivoSight as both a clinical tool and a research platform.

In the development and validation of Microneedle Array Patches, VivoSight OCT enables non-invasive, in vivo quantification of needle penetration, supporting safer and more effective device design.

For patients with Non-Melanoma Skin Cancers such as Basal Cell Carcinoma (BCC), VivoSight OCT is increasingly being used in clinical practice to provide rapid, non-invasive diagnosis and treatment monitoring, significantly reducing the need for biopsy. The continued rise in publications in this area reflects growing clinical confidence and availability.

VivoSight OCT also plays a vital role in the highly competitive cosmetics and skin-quality sector, where it supports robust, objective validation of product performance and claims.

To learn more, download the full VivoSight OCT Publications List.